Aera Therapeutics Stock

aeratx.comHealthcareFounded: 2021

Aera Therapeutics is a biotechnology and research company that develops new ways to deliver genetic medicine into cells. Through Aera’s proprietary protein nanoparticle (PNP) delivery platform, the Boston-based company is working to improve the treatment of human disease. The PNP platform is applied across a range of therapeutic applications.

Register for Details

For more details on financing and valuation for Aera Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Aera Therapeutics.

Register Today


Management Team

Akin Akinc Ph.D
Chief Executive Officer
Feng Zhang Ph.D

Other companies like Aera Therapeutics in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


A privately held biotech company called Aera Therapeutics came out of stealth recently to debut a type of protein nanoparticle that it believes can be used to ferry all sorts of genetic medicines around the body.
Led by a 20-year Alnylam veteran, Aera Therapeutics has emerged with $193 million in hand and hopes of unlocking genetic medicine’s fullest potential.
Feng Zhang, PhD, institute member at the Broad Institute and HHMI Investigator, has an uncanny ability to be in the middle of (or on the leading edge of) the hottest topics in biological research.